Natera
OrganizationHeard in 6 episodes across 5 shows since Sep 2026
Natera, Inc. is a clinical genetic testing company headquartered in Austin, Texas. It develops non-invasive, cell-free DNA testing and bioinformatics technologies for applications in women’s health, oncology, and organ health.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 0 |
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 2 |
| Oct 2026 | 4 |
Email alert
Email me when Natera comes up on a podcast
One email a week at most, with the new episodes that mention Natera. Free, no account needed, unsubscribe in one click.
What experts have said about Natera
2 statements · 1 positive · 1 mixed
Natera stock has further upside potential.
“This oncology play has room to run.”
Open the episode · Tech Earnings Weigh on the AI Trade 10/29/26Listen at 41:36
Investors should wait for a Natera pullback before buying.
“I think it's just run to the point where I can't justify chasing it. But it is definitely worth waiting for a pullback and then doing some buying.”
Open the episode · Mad Money w/ Jim Cramer 9/3/26Listen at 25:05
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
6 episodes featuring Natera, newest first
- Oct 29, 2026
Tech earnings demand proof behind the AI tradeHalftime ReportOct 29, 2026 - Oct 27, 2026
Anthropic’s filing tests the durability of the AI tradeThe Compound and FriendsOct 27, 2026 - Oct 9, 2026
AI rally faces concentration, spending and valuation testsHalftime ReportOct 9, 2026 - Oct 6, 2026
Broad rally tests whether market breadth can keep paceStock Market Today With IBDOct 6, 2026 - Sep 30, 2026
AI’s Token Economy Puts NVIDIA’s Full System to the TestMonetary Matters with Jack FarleySep 30, 2026 - Sep 3, 2026
Rate expectations put stocks and growth stories under pressureMad Money w/ Jim CramerSep 3, 2026